39 results on '"Chanan-Khan, Asher"'
Search Results
2. Monoclonal antibody utilization characteristics in patients with multiple myeloma
3. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
4. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis
5. Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15
6. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
7. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes
8. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
9. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells
10. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs
11. Implementing individualized medicine into the medical practice
12. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
13. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
14. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
15. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups
16. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner
17. Monoallelic and Biallelic Deletions of 13q14.3 in Chronic Lymphocytic Leukemia: FISH vs miRNA RT-qPCR Detection
18. Reply to tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
19. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
20. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
21. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
22. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
23. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
24. Development of target-specific treatments in multiple myeloma
25. Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide
26. Plasma cell leukaemia and other aggressive plasma cell malignancies
27. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
28. Treatment options for multiple myeloma patients with high-risk disease
29. Extent of Disease Burden Determined With Magnetic Resonance Imaging of the Bone Marrow is Predictive of Survival Outcome in Patients With Multiple Myeloma
30. Remission Induction With Lenalidomide Alone in a Patient With Previously Untreated Plasmablastic Myeloma: A Case Report
31. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
32. Pegylated Liposomal Doxorubicin and Immunomodulatory Drug Combinations in Multiple Myeloma: Rationale and Clinical Experience
33. Bortezomib in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Multiple Myeloma
34. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
35. Supportive Care in Multiple Myeloma
36. Pro-apoptotic therapy with the oligonucleotide Genasense™ (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab
37. Clinical Characteristics of Gastrointestinal Lymphomas Associated with AIDS (GI-ARL) and the Impact of HAART
38. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Restores Allostimulatory Function to Accessory Cells in Patients with AIDS
39. Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.